Natco Pharma Ltd. (NATP)

Currency in INR
886.05
+8.55(+0.97%)
Real-time Data·
Advertisement
NATP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
879.00900.00
52 wk Range
789.001,226.80
Key Statistics
Bid/Ask
886.05 / 886.10
Prev. Close
877.5
Open
879.3
Day's Range
879-900
52 wk Range
789-1,226.8
Volume
243.76K
Average Volume (3m)
704.91K
1-Year Change
-0.4199%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NATP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,004.44
Upside
+13.36%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Natco Pharma Ltd. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
3 Hold
3 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1,004.44
(+13.36% Upside)

Natco Pharma Ltd. Earnings Call Summary for Q1/2027

  • NATCO Pharma Q1 FY2027 revenue plunged 43% YoY to INR 794.4 crores due to lower lenalidomide sales; stock dropped 5.1% to $903.15.
  • EBITDA margin improved to 30.9% with normalized PAT up 34% QoQ, driven by double-digit base business growth in oncology and semaglutide.
  • Brazil revenue surged 180% YoY to INR 178 crores; domestic business grew to INR 136 crores with 25% volume growth expected for FY2027.
  • Management maintained full-year guidance of INR 3,300-3,400 crores; carfilzomib launch on track for 2027, olaparib trial expected within two months.
  • Company plans INR 2,000 crore fundraise for M&A and debt repayment; CEO emphasized long-term pipeline value materializing in 2-3 years.
Last Updated: 14/08/2026, 14:06
Read Full Transcript

Earnings

Latest Release
14/08/2026
EPS / Forecast
11.50 / 6.40
Revenue / Forecast
7.35B / 7.55B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 63.89%
Dividend Yield
0.51%
Industry Median 0.66%
Annualised payout
4.50
Paid unevenly
5-Years Growth
-5.59%
Growth Streak

Compare NATP to Peers and Sector

Metrics to compare
NATP
Peers
Sector
Relationship
P/E Ratio
13.7x36.2x−0.3x
PEG Ratio
−0.420.790.00
Price/Book
1.7x4.7x2.6x
Price / LTM Sales
4.5x4.4x3.1x
Upside (Analyst Target)
18.9%7.0%47.6%
Fair Value Upside
Unlock0.1%5.6%Unlock

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Employees
4199
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14.70M8.21%13.04B
Other Institutional Investors
47.62M26.59%42.23B
Public Companies & Retail Investors
116.79M65.21%103.58B
Total
179.11M100.00%158.84B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Time Cap Pharma Labs Ltd.9.59%17,175,42015,232,021
Natsoft Information Systems Pvt. Ltd.8.81%15,784,90013,998,839

People Also Watch

80.960
BMBK
+0.85%
155.45
CESC
-0.74%
202.48
BE
-2.01%
1,912.30
IPCA
+0.64%
1,607.20
ARBN
-0.05%

FAQ

What Is the Natco Pharma (NSE: NATP) Share Price Today?

The Natco Pharma stock price today is 886.05 INR.

What Stock Exchange Does Natco Pharma (NATP) Trade On?

Natco Pharma is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Natco Pharma?

The stock symbol (also called a 'ticker') for Natco Pharma is "NATP."

Does Natco Pharma Pay Dividends? What’s The Current NATP Dividend Yield?

Yes, NATP Pays Dividends to its Shareholders. The current Natco Pharma dividend yield is 0.51%.

What Is the Current Natco Pharma Market Capitalisation?

As of today, Natco Pharma (NSE: NATP) market cap is 159.47B INR.

What Is Natco Pharma's (NATP) Earnings Per Share (TTM)?

The Natco Pharma EPS is currently 63.89 (Trailing Twelve Months).

When Is the Next Natco Pharma Earnings Date?

Natco Pharma's next earnings report will be released on 17/11/2026.

Is NATP a Buy or Sell From a Technical Analyst Perspective?

Based on today's Natco Pharma moving averages and other technical indicators, the daily buy/sell signal for NATP stock is Strong Sell.

How Many Times Has Natco Pharma Stock Split?

Natco Pharma has split 1 times. (See the NATP stock split history page for full effective split date and price information.)

How Many Employees Does Natco Pharma Have?

Natco Pharma has 4199 employees, based on their latest Companies House report.

What is the current trading status of Natco Pharma (NSE: NATP)?

As of 21/08/2026, Natco Pharma (NATP) is trading at a share price of 886.05 INR, with a previous close of 877.50 INR. The stock has fluctuated within a day range of 879.00 INR to 900.00 INR, while its 52-week range spans from 789.00 INR to 1,226.80 INR.

What Is Natco Pharma (NATP) Price Target According to Analysts?

The average 12-month price target for Natco Pharma is 1,004.44 INR, with a high estimate of 1180 INR and a low estimate of 712 INR. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an +13.36% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.